Repositori URV

Identificador: imarina:2309057

Handle: https://hdl.handle.net/20.500.11797/imarina2309057

Autors:
Rueda Domínguez, AntonioAlfaro Lizaso, JCruz Merino, L de laGumà Padró, JosepQuero Blanco, CristinaGómez Codina, JoséLlanos Muñoz, MartaMartínez Banaclocha, NatividadRodríguez Abreu, DelvysProvencio Pulla, Mariano

Resum:
Hodgkin lymphoma (HL) is an uncommon B cell lymphoid malignancy representing approximately 10–15 % of all lymphomas. HL is composed of two distinct disease entities; the more commonly diagnosed classical HL and the rare nodular lymphocyte-predominant HL. An accurate assessment of the stage of disease and prognostic factors that identify patients at low or high risk for recurrence are used to optimize therapy. Patients with early stage disease are treated with combined modality strategies using abbreviated courses of combination chemotherapy followed by involved-field radiation therapy, while those with advanced stage disease receive a longer course of chemotherapy often without radiation therapy. High-dose chemotherapy (HDCT) followed by an autologous stem cell transplant (ASCT) is the standard of care for most patients who relapse following initial therapy. Brentuximab vedotin should be considered for patients who fail HDCT with ASCT.